Back

Baseline characteristics of the first one hundred and two patients enrolled in the trial DAPAgliflozin for Renal protection in Heart Transplant recipients (DAPARHT)

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 8 Heart Transplantation HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Stine Holmen

Oslo University Hospital Rikshospitalet, Oslo (Norway)

4 More presentations in this session

Presentation thumbnail
Impact of preoperative left ventricular unloading on post-transplant outcomes of candidates bridged with venoarterial extracorporeal membrane oxygenation
Doctor D. Enriquez Vazquez (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
The association between body mass index, body composition and exercise capacity in heart transplant recipients
Doctor M. Flesvig Holt (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Prevalence and yield of genetic testing in heart transplant patients
Ms E. Silver (La Jolla, US)
Abstract Slides Video
Presentation thumbnail
Myocardial work by speckle tracking echocardiography in heart transplant recipients: association with coronary allograft vasculopathy
Doctor G. Cacioli (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 8

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Microalbuminuria in heart transplant recipients -insights from the randomized trial dapagliflozin for renal protection in heart transplant recipients (DAPARHT)
thumbnail
Congress Presentation
Effects of dapagliflozin on renal function in heart transplant recipients.
thumbnail
Congress Presentation
Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources